Literature DB >> 8855819

Loss of chromosome arm 9p DNA and analysis of the p16 and p15 cyclin-dependent kinase inhibitor genes in human parathyroid adenomas.

H Tahara1, A P Smith, R D Gaz, A Arnold.   

Abstract

Rearrangement and overexpression of the PRAD1/cyclin D1 oncogene, a cell cycle regulator, have been implicated in the pathogenesis of a subset of parathyroid adenomas. Recently, two cell cycle regulators that inhibit the cyclin D1-associated kinases cdk4 and cdk6 have been identified: p16 and p15, the products of the INK4A (also known as CDKN2, MTS1) and INK4B (also known as MTS2) putative tumor suppressor genes located on 9p21. Because inactivation of the p16 or p15 genes might be expected to result in oncogenic consequences similar to those from cyclin D1 overexpression, we examined 25 parathyroid adenomas for 1) allelic loss of polymorphic DNA loci on chromosome arm 9p, 2) homozygous deletions of the p16 and p15 genes by Southern blot analysis, and 3) mutations of the p16 and p15 genes by single strand conformational polymorphism analysis. Heterozygous allelic loss at 9p was observed in 4 of 25 adenomas (16%); their smallest shared region of deletion was 9p21-pter, which includes both the p16 and p15 genes. However, single strand conformational polymorphism analysis of all 3 exons of the p16 gene and both exons of the p15 gene failed to demonstrate mutation in any of the 25 cases, and homozygous deletions of the p16 and p15 genes, which are present in some human cancers, were not found in any parathyroid tumors. These observations indicate that inactivating mutations or homozygous deletions of the p16 and p15 genes occur uncommonly, if ever, in parathyroid adenomas; however, loss of a different tumor suppressor gene (or genes) on 9p appears to contribute to the pathogenesis of a significant percentage of these tumors.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8855819     DOI: 10.1210/jcem.81.10.8855819

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  7 in total

Review 1.  The role of estrogen in the initiation of breast cancer.

Authors:  J Russo; Irma H Russo
Journal:  J Steroid Biochem Mol Biol       Date:  2006-12       Impact factor: 4.292

Review 2.  Molecular mechanisms of primary hyperparathyroidism.

Authors:  G N Hendy
Journal:  Rev Endocr Metab Disord       Date:  2000-11       Impact factor: 6.514

3.  Frequent promoter hypermethylation of the APC and RASSF1A tumour suppressors in parathyroid tumours.

Authors:  C Christofer Juhlin; Nimrod B Kiss; Andrea Villablanca; Felix Haglund; Jörgen Nordenström; Anders Höög; Catharina Larsson
Journal:  PLoS One       Date:  2010-03-01       Impact factor: 3.240

4.  Germline and somatic mutations in cyclin-dependent kinase inhibitor genes CDKN1A, CDKN2B, and CDKN2C in sporadic parathyroid adenomas.

Authors:  Jessica Costa-Guda; Chen-Pang Soong; Vaishali I Parekh; Sunita K Agarwal; Andrew Arnold
Journal:  Horm Cancer       Date:  2013-05-29       Impact factor: 3.869

5.  The DNA methylome of benign and malignant parathyroid tumors.

Authors:  Lee F Starker; Jessica Svedlund; Robert Udelsman; Henning Dralle; Göran Akerström; Gunnar Westin; Richard P Lifton; Peyman Björklund; Tobias Carling
Journal:  Genes Chromosomes Cancer       Date:  2011-06-02       Impact factor: 5.006

6.  Evaluation of Endocrine Neoplasms Using Fine Needle Aspiration Biopsy.

Authors:  Mary E. Barcus; Celeste N. Powers
Journal:  Endocr Pathol       Date:  2000       Impact factor: 4.056

7.  Promoter hypermethylation inactivates CDKN2A, CDKN2B and RASSF1A genes in sporadic parathyroid adenomas.

Authors:  Ashutosh Kumar Arya; Sanjay Kumar Bhadada; Priyanka Singh; Naresh Sachdeva; Uma Nahar Saikia; Divya Dahiya; Arunanshu Behera; Anil Bhansali; Sudhaker D Rao
Journal:  Sci Rep       Date:  2017-06-09       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.